Background: Pancreatic cancer is a fatal tumor, and the status of perineural invasion (PNI) of pancreatic cancer was positively related to poor prognosis including overall survival and recurrence-free survival. This study aims to develop and validate a predictive model based on serum biomarkers to accurately predict the perineural invasion.
Materials And Methods: The patients from No.924 Hospital of PLA Joint Logistic Support Force were included. The predictive model was developed in the training cohort using logistic regression analysis, and then tested in the validation cohort. The area under curve (AUC), calibration curves and decision curve analysis were used to validate the predictive accuracy and clinical benefits of nomogram.
Results: A nomogram was developed using preoperative total bilirubin, preoperative blood glucose, preoperative CA19-9. It achieved good AUC values of 0.753 and 0.737 in predicting PNI in training and validation cohorts, respectively. Calibration curves showed nomogram had good uniformity of the practical probability of PNI. Decision curve analyses revealed that the nomogram provided higher diagnostic accuracy and superior net benefit compared to single indicators.
Conclusion: The present study constructed and validate a novel nomogram predicted the PNI of resectable PHAC patients with high stability and accuracy. Besides, it could better screen high-risk probability of PNI in these patients, and optimize treatment decision-making.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508025 | PMC |
| http://dx.doi.org/10.1186/s12876-023-02819-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bots in white coats: are large language models the future of patient education? a multi-center cross-sectional analysis.
Int J Surg
January 2025
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Germany.
Objectives: Every year, around 300 million surgeries are conducted worldwide, with an estimated 4.2 million deaths occurring within 30 days after surgery. Adequate patient education is crucial, but often falls short due to the stress patients experience before surgery.
View Article and Find Full Text PDFPreventing and Treating Delayed Gastric Emptying (DGE) after Pancreatic Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Ann Surg
January 2025
Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Objective: To identify strategies to prevent and treat delayed gastric emptying (DGE) after pancreatic surgery.
Background: Among all complications of pancreatic surgery, DGE has the largest impact on prolonged hospital stay. Several randomized controlled trials (RCTs) have addressed DGE after pancreatic surgery, either as primary or as secondary outcome.
KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis.
Mol Ther Oncol
March 2025
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Oncolytic adenoviral therapy is a promising approach for pancreatic cancer treatment. However, the limited capacity of murine cells to produce infectious viral progeny precludes the full evaluation of the virotherapy in a suitable immunocompetent mouse model. Here, we report that the murine KPC-I cell line, established from pancreatic tumors developed in ; ; mice, is susceptible to adenoviral replication and generates a progeny of infective virions similar to those from infected human A549 cells.
View Article and Find Full Text PDFGlobal, regional and national burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044.
Front Oncol
January 2025
The Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Background: To estimate the global burden of pancreatic cancer in 2019 and 2021 including incidence, mortality, and disability-adjusted-life-years (DALYs).
Methods: Data on pancreatic cancer incidence, mortality and DALYs were downloaded from the Global Health Data Exchange. The 95% uncertainty intervals (UIs) were reported for annual numbers and rates (per 100,000 populations).
Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.
BMC Surg
January 2025
General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Background And Aim: Hepatocellular carcinoma (HCC) is a highly immunogenic tumor and the third leading cause of cancer-related deaths worldwide with an increasing incidence. Therefore, the combination of immunotherapy with other approaches, such as anti-angiogenic agents and local area therapy, has become a new strategy for HCC treatment.
Methods: We searched PubMed and Web of Science and extracted publications relating to the radiofrequency ablation (RFA) and immunotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!